Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 3,529 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT02346422
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
Interventions
MYDICAR Phase 1, MYDICAR Phase 2, Placebo Phase 2 only
Genetic
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery

NCT00554359
View directory record Official record
Conditions
Injury of Kidney, Acute Renal Failure
Interventions
I5NP (a small interfering RNA), placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
21 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

NCT00050661
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, NB-UVB
Drug · Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

NCT01030861
View directory record Official record
Conditions
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions
Teplizumab, Placebo infusion
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

NCT02116361
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
onabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
35
States / cities
Little Rock, Alaska • Bellflower, California • Cerritos, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep

NCT02856594
View directory record Official record
Conditions
Postoperative Delirium, Sleep, Anesthesia
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

NCT01933594
View directory record Official record
Conditions
HIV Infections
Interventions
Romidepsin, Placebo for Romidepsin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

NCT05233566
View directory record Official record
Conditions
Postoperative Depression
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

NCT02517905
View directory record Official record
Conditions
Dental Pain
Interventions
Bupivacaine liposome, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
IV Ganciclovir, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Trial of Extended Release Bupivacaine for Pain Relief After Surgery

NCT02574520
View directory record Official record
Conditions
Post Operative Pain
Interventions
SABER-Bupivacaine (Part 1), SABER-Bupivacaine (Part 2), Saline Placebo, Bupivacaine HCl
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
21
States / cities
Florence, Alabama • Sheffield, Alabama • Arcadia, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis

NCT02651324
View directory record Official record
Conditions
Idiopathic Scoliosis, Post-operative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Fentanyl as an Analgesic for Cystoscopic Procedures

NCT01708122
View directory record Official record
Conditions
Pain
Interventions
Fentanyl, saline
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

NCT02100631
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
46 Years to 64 Years
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
16
States / cities
Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Not listed Not applicable Interventional

Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain

NCT01905137
View directory record Official record
Conditions
Myofascial Pelvic Pain
Interventions
Intervention-Botulinum Toxin Type A, placebo
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

NCT07762001
View directory record Official record
Conditions
Maximum Tolerated Dose, Dose Escalation
Interventions
AD-NP1, Placebo
Drug
Lead sponsor
Arjun Deb, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

NCT02985879
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Placebo, ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 3 Interventional

Optimizing Pain Treatment in Children On Mechanical Ventilation

NCT06994442
View directory record Official record
Conditions
Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid, Sedation and Analgesia
Interventions
Acetaminophen, Ketorolac, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Months to 17 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Ann Arbor, Michigan + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 4 Interventional Results available

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

NCT01045694
View directory record Official record
Conditions
Arthritis Multiple Joint
Interventions
Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

In-office Repair of Chronic Tympanic Membrane Perforations

NCT06448039
View directory record Official record
Conditions
Chronic Tympanic Membrane Perforation
Interventions
Fibroblast Growth Factor 2, Saline control
Drug
Lead sponsor
D. Bradley Welling, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

NCT00515099
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Antithymocyte globulin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 22, 2026, 10:02 AM EDT